share_log

'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks

Benzinga ·  08:01

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Merck & Co., Inc. (NYSE:MRK). "I have tremendous, tremendous faith in what Robert Davis [CEO of Merck] is doing," he added.

When asked about Teladoc Health, Inc (NYSE:TDOC), he said, "What's going on there, right now we've got this Cathie Wood, she sells the stock almost every day. She bought it much higher, it's really painful to watch."

Fortinet, Inc. (NASDAQ:FTNT) reported a "very good" quarter, he said. "I remain committed to Nikesh Arora [CEO of Palo Alto Networks] and Palo Alto Networks (NASDAQ:PANW), which I think is doing the best of all of them."

Enova International, Inc. (NYSE:ENVA) is a "little dicey," Cramer said, "A little dicey because it's untraditional lending. I am just a traditionalist. I say go with the stock that collapsed over the last week, go with Wells Fargo & Co (NYSE:WFC)."

"This is enterprise software, and, you know, there is more money being lost in enterprise software in 2024 than in any other sector, so I can't play, I'm sorry," Cramer said when asked about Bentley Systems, Incorporated (NASDAQ:BSY).

GE HealthCare Technologies Inc. (NASDAQ:GEHC) reported a "decent" quarter and has been hurt by China, he said. "I bought the worst of the three, and I'm not proud of myself."

Price Action:

  • Teladoc Health shares gained 0.7% to settle at $7.21 on Thursday.
  • Fortinet shares fell 1.8% to close at $68.68.
  • Merck shares gained 1.3% to close at $113.92.
  • Enova International shares rose 1.7% to close at $76.85.
  • GE Healthcare shares gained 3.8% to settle at $82.32 on Thursday.
  • Bentley Systems shares rose 5.1% to close at $49.25 on Thursday.
  • S&P 500 Records Best Session Since January 2023: Investor Sentiment Improves, But Greed Index Remains In 'Extreme Fear' Zone

Photo: Shutterstock

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment